| Document |
Document Title |
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/209191A1 |
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a di...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/206874A1 |
A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutra...
|
|
WO/2023/203503A1 |
The present invention relates to a process for the preparation of crystalline Form 4 of tafamidis from tafamidis meglumine salt.
|
|
WO/2023/200315A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/190976A1 |
Provided is a novel therapeutic agent that is useful for treating a chronic lung disease such as COPD or IPF.　The present invention relates to a pharmaceutical composition for treating a chronic lung disease that contains a therapeutic...
|
|
WO/2023/182775A1 |
The present invention pertains to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.
|
|
WO/2023/177217A1 |
The present invention relates to: a novel aromatic heterocyclic compound to be used in an organic light-emitting diode; and the organic light-emitting diode comprising same.
|
|
WO/2023/171980A1 |
The present invention relates to a novel tafamidis preparation method having economic feasibility even while having an excellent synthesis yield. More specifically, the present invention relates to a novel method for synthesizing tafamid...
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/152182A1 |
Present invention relates to a compound according to formula (II): and all stereoisomers, racemic mixtures, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates and polymorphs thereof, as well as pharmaceutical comp...
|
|
WO/2023/151897A1 |
The invention relates to compounds of general formula (I).
|
|
WO/2023/146844A1 |
The disclosure provides 2-amino 4-nitrolphenol and 2,4-diaminophenol derivatives, which can be used as anti-inflammatory drugs, prostaglandin E2 (PGE2) synthesis and activity inhibitors, and microsomal PGE2 synthase-1 (mPGES-1) inhibitors.
|
|
WO/2023/143741A1 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2023/144326A1 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2023/146846A1 |
The present disclosure provides use of non-steroidal anti-inflammatory compositions as described herein for used in the treatment of inflammation, inflammatory-related diseases, pain and/or fever.
|
|
WO/2023/144228A1 |
The present invention relates to a copolymer having several azide functionalities that can be prepared by cationic ring opening polymerisation. The copolymer comprises a first monomer unit and a second monomer unit which are different fr...
|
|
WO/2023/140709A1 |
The present disclosure provides a novel oxazole derivative compound having anti-Mycobacterium tuberculosis activity or a pharmaceutically acceptable salt thereof. The present disclosure also provides an antibacterial composition comprisi...
|
|
WO/2023/135603A1 |
Compounds capable of interacting with the calmodulin-PIP2 binding domain of the SK4 channel to thereby interfere with the Ca2+-dependent activation of the SK4 channel and uses thereof in downregulating an activity of an SK4 channel in a ...
|
|
WO/2023/136457A1 |
The present invention relates to a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/018472A9 |
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
|
|
WO/2023/131951A1 |
Novel non-coded amino acids derivatives having herbicidal activity, agricultural compositions, process for their manufacture and their use in crop protection are provided.
|
|
WO/2023/128885A1 |
The present invention is a synthesis method for benzoxazole based optical brighteners characterized by comprising the steps of; placing in a reactor vessel at least one acid selected from thiophene-2,5-dicarboxylic acid or stilbene-4,4'-...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/116587A1 |
A binuclear platinum complex luminescent material having the structure of chemical formula (I), applied to an organic light-emitting diode and having good luminous efficiency and long device life. Also provided is an organic electrolumin...
|
|
WO/2023/115394A1 |
A diarylamine compound and use thereof, a light extraction material, an electroluminescent device, and a display device. The structural general formula of the diarylamine compound is formula (I).
|
|
WO/2023/121022A1 |
The present invention relates to N-phenylbenzoxazolo-2-amine and N-phenyloxazolopyridin-2-amine derivatives as novel leukotriene B4 receptor inhibitors, and use thereof.
|
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/114977A1 |
Described herein are compounds useful as S1PR4 receptor antagonists, pharmaceutical compositions comprising said compounds, methods of making said compounds and pharmaceutical compositions, and methods of using said compounds and pharmac...
|
|
WO/2023/111996A1 |
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one ...
|
|
WO/2023/106625A1 |
The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/097194A2 |
This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2023/092175A1 |
The invention relates generally to a compound of Formula (I), wherein R1 is a bicyclic fused heterocyclic moiety and R2 is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/091534A1 |
The present disclosure relates to a solid state form of Tafamidis, processes for preparation thereof and pharmaceutical compositions thereof.
|
|
WO/2023/078909A1 |
The present invention relates to compounds of formula (I), a delivery system based on photoresponsive cyclic acetal or ketal compounds capable of liberating in a controlled manner active volatile carbonyl compounds into the surrounding u...
|
|
WO/2023/077726A1 |
The present invention provides an organic compound, a light extraction layer material, and an organic electronic device. The structure of the organic compound is represented as general formula (1). The organic compound can be used as the...
|
|
WO/2023/073115A1 |
The present invention relates to the use of the compound of the formula (I) and the composition thereof as control agent for plant diseases caused by fungi, oomycetes and bacteria. Plant pathogens produce self-aggregating proteins, like ...
|
|
WO/2023/072143A1 |
Disclosed in the present invention are a camptothecin derivative intermediate, and a preparation method therefor and the use thereof. The structural formula of the camptothecin derivative intermediate of the present invention is as shown...
|
|
WO/2023/069721A2 |
Provided herein are USP28 inhibitors, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment and/or diagnosis.
|
|
WO/2023/062627A1 |
Provided herein are compounds that inhibit the protein-protein interaction of serine acetyltransferase (SAT) with O-acetyl serine sulfhydrylase (OASS), and can therefore be used as herbicides.
|
|
WO/2023/061999A1 |
The present invention discloses a distinct mode of action of a nickel catalyst to forge C-0 bonds to unlock the mild utilization of N2O as O-atom transfer reagent in the synthesis of complex phenols from the corresponding aryl halides.
|
|
WO/2023/063112A1 |
The present disclosure provides an organic compound represented by general formula [1]. In formula [1], R1 and R2 are each independently selected from a hydrogen atom, an alkyl group, or the like. R3 are each independently selected from ...
|
|
WO/2022/187804A9 |
Compounds which are benzoxazolone derivatives are disclosed, including compounds of the following genus: The compounds possess anti-inflammasome properties and exhibit anti-fibrotic and anti-proliferative effects. They are useful in inhi...
|
|
WO/2023/052104A1 |
The present invention provides a process for producing an oxazole compound of formula (I), wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents. The process according to the present invention is simpl...
|
|
WO/2023/052103A1 |
The present invention provides a new compound of formula (I), and a process for producing the compound of formula (I) and a process for producing oxazole compounds by using the compound of formula (I),wherein R is H, or lower alkyl or ar...
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
